Literature DB >> 9640748

A joint US-UK study of home telenursing.

R Wootton1, M Loane, F Mair, A Allen, G Doolittle, M Begley, A McLernan, M Moutray, S Harrisson.   

Abstract

Nursing notes for patients nursed at home in the USA and the UK were reviewed using an abstraction instrument developed and tested in the US. More than 1700 episodes of patient care at home were reviewed: 906 in the US and 839 in the UK. Preliminary data suggest that in the US approximately 45% of home nursing visits could be done via telemedicine, while the figure is lower in the UK, less than 15%. Pilot trials of an analogue video-telephone in Kansas City and Belfast suggest that even relatively low-quality compressed video may be useful for home nursing. Clearly, there are differences between the two countries which merit further study, but there is evidence to suggest that telemedicine may have a role in the delivery of home health care.

Entities:  

Mesh:

Year:  1998        PMID: 9640748     DOI: 10.1258/1357633981931588

Source DB:  PubMed          Journal:  J Telemed Telecare        ISSN: 1357-633X            Impact factor:   6.184


  3 in total

Review 1.  Applying research evidence to optimize telehomecare.

Authors:  Kathryn H Bowles; Amy C Baugh
Journal:  J Cardiovasc Nurs       Date:  2007 Jan-Feb       Impact factor: 2.083

2.  Clinical effectiveness, access to, and satisfaction with care using a telehomecare substitution intervention: a randomized controlled trial.

Authors:  Kathryn H Bowles; Alexandra L Hanlon; Henry A Glick; Mary D Naylor; Melissa O'Connor; Barbara Riegel; Nai-Wei Shih; Mark G Weiner
Journal:  Int J Telemed Appl       Date:  2011-12-01

3.  Investigating the cost-effectiveness of videotelephone based support for newly diagnosed paediatric oncology patients and their families: design of a randomised controlled trial.

Authors:  Mark Bensink; Richard Wootton; Helen Irving; Andrew Hallahan; Deborah Theodoros; Trevor Russell; Paul Scuffham; Adrian G Barnett
Journal:  BMC Health Serv Res       Date:  2007-03-05       Impact factor: 2.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.